1887

Journal of General Virology header logo

Volume 88, Issue 3

Seroprevalence of human papillomaviruses and and cervical cancer risk: nested case–control study Free

Abstract

A nested case–control study of invasive and cervical cancer was performed within a community-based cohort of 13 595 Taiwanese women assembled in 1991, with a follow-up period of 9 years. Baseline serum or plasma samples were analysed for antibodies against human papillomavirus (HPV) types 6, 16 and 18 and . In total, 114 cases (42 incident cases identified during follow-up and 72 prevalent cases identified at baseline) and 519 matched controls were included in the study. HPV-16 seropositivity was strongly associated with cervical cancer (OR=6.33; 95 % CI 3.45–11.62). Overall, was not associated with cervical cancer, but was associated with cervical cancer in analyses restricted to incident cases of cancer (OR=2.94; 95 % CI 1.17–7.42) or to cases in which serum samples were analysed (OR=3.13; 95 % CI 1.16–8.47). An antagonistic interaction between HPV-6 and -16 was found in a multiplicative model. These results suggest that different HPV types might interfere in cervical carcinogenesis and that is associated with cervical cancer in prospective studies, and support the notion that HPV-16 seropositivity is strongly associated with cervical cancer.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82503-0
2007-03-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/3/814.html?itemId=/content/journal/jgv/10.1099/vir.0.82503-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam V., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J., Lehtinen M., Dillner J. 1998; Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177:1710–1714 [CrossRef]
     [Google Scholar]
  2. Andersson-Ellström A., Dillner J., Hagmar B., Schiller J. T., Sapp M., Forssman L., Milsom I. 1996; Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23:234–238 [CrossRef]
     [Google Scholar]
  3. Anttila T., Saikku P., Koskela P., Bloigu A., Dillner J., Ikaheimo I., Jellum E., Lehtinen M., Lenner P. 2001; Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285:47–51 [CrossRef]
     [Google Scholar]
  4. Bosch F. X., Manos M. M., Muñoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. 1995; Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87:796–802 [CrossRef]
     [Google Scholar]
  5. Clifford G. M., Smith J., Aguado T., Franceschi S. 2003; Comparison of HPV type distribution in highgrade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89:101–105 [CrossRef]
     [Google Scholar]
  6. Combita A.-L., Bravo M.-M., Touzé A., Orozco O., Coursaget P. 2002; Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 97:796–803 [CrossRef]
     [Google Scholar]
  7. Dillner J., Wiklund F., Lenner P., Eklund C., Fredriksson-Shanazarian V., Schiller J. T., Hibma M., Hallmans G., Stendahl U. 1995; Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 60:377–382
     [Google Scholar]
  8. Dillner J., Kallings I., Brihmer C., Sikström B., Koskela P., Lehtinen M., Schiller J. T., Sapp M., Mårdh P. 1996; Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 173:1394–1398 [CrossRef]
     [Google Scholar]
  9. Dillner J., Lehtinen M., Björge T., Luostarinen T., Youngman L., Jellum E., Koskela P., Gislefoss R. E., Hallmans G. 1997; Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89:1293–1299 [CrossRef]
     [Google Scholar]
  10. Evander M., Edlund K., Gustafsson A., Jonsson M., Karlsson R., Rylander E., Wadell G. 1995; Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 171:1026–1030 [CrossRef]
     [Google Scholar]
  11. Grabowska K., Wang X., Jacobsson A., Dillner J. 2002; Evaluation of cost-precision ratios of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 271:1–15 [CrossRef]
     [Google Scholar]
  12. Herrero R., Hildesheim A., Bratti C., Sherman M. E., Hutchinson M., Morales J., Balmaceda I., Greenberg M. D., Alfaro M. 2000; Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92:464–474 [CrossRef]
     [Google Scholar]
  13. Hildesheim A., Schiffman M., Gravitt P., Glass A. G., Greer C. E., Zhang T., Scott D. R., Rush B. B., Lawler P. 1994; Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169:235–240 [CrossRef]
     [Google Scholar]
  14. Ho G. Y., Bierman R., Beardsley L., Chang C., Burk R. 1998; Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423–428 [CrossRef]
     [Google Scholar]
  15. Hosmer D. W., Lemeshow S. 1992; Confidence interval estimation of interaction. Epidemiology 3:452–456 [CrossRef]
     [Google Scholar]
  16. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissman L., Lowy D. R., Schiller J. T. 1993; Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67:6929–6936
     [Google Scholar]
  17. Kjellberg L., Wang Z., Wiklund F., Edlund K., Angstrom T., Lenner P., Sjoberg I., Hallmans G., Wallin K. L. 1999; Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case–control study. J Gen Virol 80:391–398
     [Google Scholar]
  18. Koskela P., Anttila T., Bjorge T., Brunsvig A., Dillner J., Hakama M., Hakulinen T., Jellum E., Lehtinen M. 2000; Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 85:35–39 [CrossRef]
     [Google Scholar]
  19. Lehtinen M., Dillner J., Knekt P., Luostarinen T., Aromaa A., Kirnbauer R., Koskela P., Paavonen J., Peto R. 1996; Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case–control study. BMJ 312:537–539 [CrossRef]
     [Google Scholar]
  20. Liaw K. L., Hsing A. W., Chen C. J., Schiffman M. H., Zhang T. Y., Hsieh C. Y., Greer C. E., You S. L., Huang T. W. 1995; Human papillomavirus and cervical neoplasia: a case–control study in Taiwan. Int J Cancer 62:565–571 [CrossRef]
     [Google Scholar]
  21. Luostarinen T., Af Geijersstam V., Björge T., Eklund C., Hakama M., Hakulinen T., Jellum E., Koskela P., Paavonen J. 1999; No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 80:818–822 [CrossRef]
     [Google Scholar]
  22. Luostarinen T., Lehtinen M., Björge T., Abeler V., Hakama M., Hallmans G., Jellum E., Koskela P., Lenner P. 2004; Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 40:1058–1065 [CrossRef]
     [Google Scholar]
  23. Matsumoto K., Yoshikawa H., Yasugi T., Nakagawa S., Kawana K., Takeoka A., Yaegashi N., Iwasaka T., Kanazawa K. 2003; IgG antibodies to human papillomavirus 16, 52, 58 and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan. J Med Virol 69:441–446 [CrossRef]
     [Google Scholar]
  24. Muñoz N., Bosch F. X., de Sanjosé S., Herrero R., Castellsagué X., Shah K. V., Snijders P. J., Meijer C. J. 2003; Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527 [CrossRef]
     [Google Scholar]
  25. Nauclér P., da Costa F. M., Ljungberg O., Bugalho A., Dillner J. 2004; Human papillomavirus genotyped in cervical cancers in Mozambique. J Gen Virol 85:2189–2190 [CrossRef]
     [Google Scholar]
  26. Olsen A. O. O., Dillner J., Gjöen K., Magnus P. 1997; Seropositivity against HPV16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med 73:131–135
     [Google Scholar]
  27. Paavonen J., Eggert-Kruse W. 1999; Chlamydia trachomatis : impact on human reproduction. Hum Reprod Update 5:433–447 [CrossRef]
     [Google Scholar]
  28. Parkin D. M., Pisani P., Ferlay J. 1993; Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606 [CrossRef]
     [Google Scholar]
  29. Puolakkainen M., Vesterinen E., Purola E., Saikku P., Paavonen J. 1986; Persistence of chlamydial antibodies after pelvic inflammatory disease. J Clin Microbiol 23:924–928
     [Google Scholar]
  30. Rothman K. J., Greenland S. 1998; Concepts of interaction. In Modern Epidemiology , 2nd edn. pp 329–342 Edited by Rothman K. J., Greenland S. Philadelphia, PA: Lippincott–Raven;
     [Google Scholar]
  31. Schiffman M. H. 1992; Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 84:394–398 [CrossRef]
     [Google Scholar]
  32. Shah K. V., Viscidi R. P., Alberg A. J., Helzlsouer K. J., Comstock G. W. 1997; Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 6:233–237
     [Google Scholar]
  33. Sigurgeirsson B., Lindelöf B., Eklund G. 1991; Condylomata acuminata and risk of cancer: an epidemiological study. BMJ 303:341–344 [CrossRef]
     [Google Scholar]
  34. Silins I., Wang Z., Avall-Lundqvist E., Frankendal B., Vikmanis U., Sapp M., Schiller J. T., Dillner J. 1999; Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 80:2931–2936
     [Google Scholar]
  35. Silins I., Tedeschi R. M., Kallings I., Dillner J. 2002; Clustering of seropositivities for sexually transmitted infections. Sex Transm Dis 29:207–211 [CrossRef]
     [Google Scholar]
  36. Silins I., Wang X., Tadesse A., Jansen K. U., Schiller J. T., Åvall-Lundqvist E., Frankendahl B., Dillner J. 2004; A population-based study of cervcal carcinoma and HPV infection in Latvia. Gynecol Oncol 93:484–492 [CrossRef]
     [Google Scholar]
  37. Silins I., Ryd W., Strand A., Wadell G., Törnberg S., Hansson B. G., Wang X., Arnheim L., Dahl V. 2005; Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 116:110–115 [CrossRef]
     [Google Scholar]
  38. Smith J. S., Bosetti C., Muñoz N., Herrero R., Bosch F. X., Eluf-Neto J., Meijer C. J., Van Den Brule A. J., Franceschi S. 2004; Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case–control study. Int J Cancer 111:431–439 [CrossRef]
     [Google Scholar]
  39. Sun C. A., Liu J., Wu D., Nieh S., Yu C., Chu T. 2002; Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 76:41–47 [CrossRef]
     [Google Scholar]
  40. Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., Snijders P. J., Peto J., Meijer C. J., Muñoz N. 1999; Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19 [CrossRef]
     [Google Scholar]
  41. Wang P. D., Lin R. S. 1996; a Epidemiology of cervical cancer in Taiwan. Gynecol Oncol 62:344–352 [CrossRef]
     [Google Scholar]
  42. Wang P. D., Lin R. S. 1996; b Risk factors for cervical intraepithelial neoplasia in Taiwan. Gynecol Oncol 62:10–18 [CrossRef]
     [Google Scholar]
  43. Wang S. P., Grayston J. T. 1970; Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol 70:367–374 [CrossRef]
     [Google Scholar]
  44. Wang Z., Konya J., Åvall-Lundkvist E., Sapp M., Dillner J., Dillner L. 1997; Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 52:436–440 [CrossRef]
     [Google Scholar]
  45. Woodward M. 1999 Epidemiology: Study Design and Data Analysis Boca Raton, FL: Chapman & Hall/CRC;
     [Google Scholar]
  46. Zenilman J. M. 2001; Chlamydia and cervical cancer: a real association?. JAMA 285:81–83 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82503-0
Loading
Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case–control study
J. Gen. Virol. 88, 814 (2007); https://doi.org/10.1099/vir.0.82503-0
/content/journal/jgv/10.1099/vir.0.82503-0
/content/journal/jgv/10.1099/vir.0.82503-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error